Iranian Society of Gynecology Oncology

Document Type : Original Research Article


1 Professor of Gynecology-Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Obstetrician & Gynecologist, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 MD, Internist, Imam Hossein hospital, Iran university of medical Sciences

4 MS.c of developmental biology, Science and Research University of Tehran, Tehran, Iran

5 Fellowship of Laparoscopy, Tehran University of Medical Sciences Tehran,Iran

6 Department Obstetrics & Gynecology, university of Shahid beheshti , Mahdieh Hospital ,Tehran, Iran


Cancer survivorship care tries to discover improved healthy lifestyles for cancer patients, rather than just managing the complications; thus, it seems necessary to identify the aspects associated with general well-being in order to design proper care, and confront difficulties that cancer survivors encounter such as anxiety, depression, cognitive dysfunction, weakness and fatigue, pain, sexual dysfunction, and sleep disorders (1-4). Cancer survivorship assessment from the National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines. survivorship, version 2.2020) is one of the most common and valid tools for measuring the quality of life in cancer survivors (3-6).
Gynecological cancer survivors have been growing, as a result of advancements in national cancer screening strategies, resulting in early-stage diagnosis, and cancer treatments developments; thus, general mortality to incidence ratios have been declined from 2000 to 2015, in Iran. However, lack of a valid documented assessment tool to measure their requirements for supportive care is detected (7). It seems indispensable to provide a translated adapted version of NCCN survivorship questionnaire, to offer the Iranian cancer care providers have the prospect in comparison and approaches in a transcultural framework. The present study proposed to represent a renovated double back translation to revise and culturally adapt the original English version of cancer survivors’ assessment questionnaire into the Persian version in order to achieve a reliable tool that meets the clinical research needs of Iranian researchers at the desired level. The aim was to develop a comprehensive scale that comprises all features of gynecologic cancer survivors` requirements in Iranian population, equivalent to NCCN guideline hypothetical concept.


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68(1):7-30. [DOI:10.3322/caac.21442] [PMID]
2. Riba MB, Donovan KA, Andersen B, Braun I, Breitbart WS, Brewer BW, et al. Distress management, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(10):1229-49. [DOI:10.6004/jnccn.2019.0048] [PMID] [PMCID]
3. Grover S, Hill-Kayser CE, Vachani C, Hampshire MK, DiLullo GA, Metz JM. Patient reported late effects of gynecological cancer treatment. Gynecol Oncol. 2012;124(3):399-403. [DOI:10.1016/j.ygyno.2011.11.034] [PMID]
4. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition: National Academies Press; 2005.
5. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship. J Clin Oncol. 2017;35(18):1978-81. [DOI:10.1200/JCO.2016.72.1373] [PMID] [PMCID]
6. Chan R, Nekhlyudov L. Overview of cancer survivorship care for primary care and oncology providers. 2021.
7. Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, et al. NCCN guidelines insights: survivorship, version 2.2020: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2020;18(8):1016-23. [DOI:10.6004/jnccn.2020.0037] [PMID] [PMCID]
8. Truant TL, Fitch MI, O'Leary C, Stewart J. Global perspectives on cancer survivorship: From lost in transition to leading into the future. Can Oncol Nurs J. 2017;27(3):287-94.
9. Razmi N, Hasanzadeh M. Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches. Trends Analyt Chem. 2018;108:1-12. [DOI:10.1016/j.trac.2018.08.017]
10. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203. [DOI:10.1016/S2214-109X(19)30482-6] [PMID]
11. Cardoso F, van 't Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J-Y, et al. MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. J Clin Oncol. 2020;38(15_suppl):506. [DOI:10.1200/JCO.2020.38.15_suppl.506]
12. Wijayabahu AT, Egan KM, Yaghjyan L. Uterine cancer in breast cancer survivors: a systematic review. Breast Cancer Res Treat. 2020;180(1):1-19. [DOI:10.1007/s10549-019-05516-1] [PMID]
13. Filippova OT, Leitao MM. The current clinical approach to newly diagnosed uterine cancer. Expert Rev Anticancer Ther. 2020;20(7):581-90. [DOI:10.1080/14737140.2020.1782750] [PMID] [PMCID]
14. Lewin SN, Wright JD. Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. Obstet Gynecol. 2011;117(5). [DOI:10.1097/AOG.0b013e3182167973] [PMID]
15. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105-43. [DOI:10.1016/S0020-7292(06)60031-3]
16. Rahmani A, Ferguson C, Jabarzadeh F, Mohammadpoorasl A, Moradi N, Pakpour V. Supportive care needs of Iranian cancer patients. Indian J Palliat Care. 2014;20(3):224-8. [DOI:10.4103/0973-1075.138400] [PMID] [PMCID]
17. Marcoux V, Chouinard M-C, Diadiou F, Dufour I, Hudon C. Screening tools to identify patients with complex health needs at risk of high use of health care services: a scoping review. PLoS One. 2017;12(11):e0188663. [DOI:10.1371/journal.pone.0188663] [PMID] [PMCID]
18. Syse A, Geller B. A Cross-Cultural Perspective on Challenges Facing Comparative Cancer Survivorship Research. J Cancer Epidemiol. 2011;2011:689025. [DOI:10.1155/2011/689025] [PMID] [PMCID]
19. Guidry JJ, Torrence W, Herbelin S. Closing the divide: Diverse populations and cancer survivorship. Cancer. 2005;104(S11):2577-83. [DOI:10.1002/cncr.21251] [PMID]
20. Haryani H, Afiyanti Y, Besral B, Gayatri D, Wahidi KR, Pramiasti H, et al. Cross-cultural adaptation and validation of the cancer survivors' unmet needs measure among gynecological cancer patients in Indonesia. Arch Oncol. 2020;26(2):23-9. [DOI:10.2298/AOO190531011H]
21. Hambleton RK, Kanjee A. Increasing the validity of cross-cultural assessments: Use of improved methods for test adaptations. Eur J Psychol Assess. 1995;11(3):147-57. [DOI:10.1027/1015-5759.11.3.147]
22. Hilton A, Skrutkowski M. Translating Instruments Into Other Languages: Development and Testing Processes. Cancer Nurs. 2002;25(1). [DOI:10.1097/00002820-200202000-00001] [PMID]
23. Geisinger KF. Cross-cultural normative assessment: Translation and adaptation issues influencing the normative interpretation of assessment instruments. Psychol Assess. 1994;6(4):304. [DOI:10.1037/1040-3590.6.4.304]
24. Nicholson NS. Translation and Interpretation. Annu Rev Linguist. 1995;15:42 - 62. [DOI:10.1017/S0267190500002609]